RVTY

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2002, for PerkinElmer, Inc. (Note: The filing metadata lists "REVVITY, INC.", but the document text explicitly identifies the registrant as PerkinElmer, Inc.). The company operates through three strategic business units: Life Sciences, Optoelectronics, and Analytical Instruments. The quarter included the integration of the Packard BioScience Company acquisition completed in late 2001 and the classification of the Fluid Sciences and Security and Detection Systems businesses as discontinued operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased 9% year-over-year. Organic revenue fell 11%, driven by declines in the Optoelectronics and Analytical Instruments segments, partially offset by the inclusion of Packard in the Life Sciences segment.
• Profitability Shift: The company reported a net loss of $29.6 million compared to a net income of $23.5 million in the prior year. This reversal was primarily due to a $23.5 million inventory adjustment in the Optoelectronics segment, $10.7 million in restructuring charges, and an extraordinary loss of $3.6 million from debt redemption.
• Cost Structure: Reported cost of sales increased to 65% of sales from 55% in the prior year, largely due to the inventory write-down and lower capacity utilization. Adjusted cost of sales (excluding the write-down) was 57% of sales.
• Debt and Liquidity: Short-term debt increased significantly to $221.6 million, funded by commercial paper borrowings to finance operations and the redemption of $118 million in senior subordinated notes.

Guidance, Outlook, and Risks

• Restructuring: The company recorded $10.7 million in restructuring charges in Q1 2002 related to workforce reductions and facility closures. Cash outlays for these actions totaled $22.1 million, with remaining actions expected to occur in fiscal 2002.
• Accounting Changes: The company adopted SFAS No. 142, ceasing the amortization of goodwill effective January 1, 2002. This resulted in a reduction of amortization expense compared to the prior year.
• Segment Performance:
  • Life Sciences: Revenues increased 69% due to the Packard acquisition, though organic growth was flat. Operating loss of $1.4 million was driven by nonrecurring charges.
  • Optoelectronics: Revenues dropped 40% due to market declines in telecom and semiconductor sectors. Reported operating loss of $34.1 million included the $23.5 million inventory adjustment.
  • Analytical Instruments: Revenues decreased 20% due to softening demand in pharmaceutical and chemical sectors.
• Liquidity Outlook: Management expects to refinance short-term debt in the second quarter of 2002 through commercial paper, other short-term borrowings, or proceeds from business sales. The company maintains $370 million in unsecured credit lines.
• Risks: Key risks include foreign exchange volatility, market demand fluctuations in life sciences and optoelectronics, and the successful integration of acquired businesses.

Investor Verification Checklist

• Verify the impact of the $23.5 million inventory adjustment in the Optoelectronics segment on future cost of sales and margin recovery.
• Monitor the integration progress of the Packard BioScience acquisition and its contribution to organic growth in the Life Sciences segment.
• Assess the company's ability to refinance the $221.6 million in short-term commercial paper debt as planned in Q2 2002.
• Review the execution of the $10.7 million restructuring plan and the associated cash outflows to ensure cost reduction targets are met.
• Confirm the status of the discontinued operations (Fluid Sciences and Security and Detection Systems) and the timeline for their sale.